{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:13:46Z","timestamp":1785777226484,"version":"3.56.0"},"reference-count":19,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case presentation<\/jats:title>\n                  <jats:p>A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion. Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had missense mutation in BTN2A1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This case supports rechallenge of programme death receptor 1 inhibitor in cases of previous CPI sensitivity and gives molecular insights.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-000713","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T05:25:25Z","timestamp":1584077125000},"page":"e000713","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab"],"prefix":"10.1136","volume":"8","author":[{"given":"Anna","family":"Minchom","sequence":"first","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wotherspoon","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Miranda","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Riisnaes","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bertan","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Pereira","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Clarke","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Baker","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Ern","family":"Ang","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicos","family":"Fotiadis","sequence":"additional","affiliation":[{"name":"Department of Radiology, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-5379","authenticated-orcid":false,"given":"Suzanne","family":"Carreira","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[{"name":"Lung Unit, Royal Marsden Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Lung Unit, Royal Marsden Hospital, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Lopez","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Royal Marsden Hospital\/ Institute of Cancer Research, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"2025100302470132000_8.1.e000713.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv199"},{"key":"2025100302470132000_8.1.e000713.2","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100302470132000_8.1.e000713.3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tlcr.2017.05.02","article-title":"Immunotherapy for malignant pleural mesothelioma: current status and future directions","volume":"6","author":"Dozier","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"2025100302470132000_8.1.e000713.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.42"},{"key":"2025100302470132000_8.1.e000713.5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1B trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025100302470132000_8.1.e000713.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"2025100302470132000_8.1.e000713.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2010.03255.x"},{"key":"2025100302470132000_8.1.e000713.8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cei.13060","article-title":"In-vitro effect of pembrolizumab on different T regulatory cell subsets","volume":"191","author":"Toor","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"2025100302470132000_8.1.e000713.9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064"},{"key":"2025100302470132000_8.1.e000713.10","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result","volume":"13","author":"Nowak","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"key":"2025100302470132000_8.1.e000713.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"2025100302470132000_8.1.e000713.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8"},{"key":"2025100302470132000_8.1.e000713.13","doi-asserted-by":"crossref","unstructured":"Osa A , Uenami T , Koyama S , et al . Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients. JCI Insight 2018;3.doi:10.1172\/jci.insight.59125","DOI":"10.1172\/jci.insight.59125"},{"key":"2025100302470132000_8.1.e000713.14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-Year follow-up of nivolumab in previously treated advanced Non\u2013Small-Cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"JCO"},{"key":"2025100302470132000_8.1.e000713.15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0804"},{"key":"2025100302470132000_8.1.e000713.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025100302470132000_8.1.e000713.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150435"},{"key":"2025100302470132000_8.1.e000713.18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025100302470132000_8.1.e000713.19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2018.06.005","article-title":"Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression","volume":"101","author":"Bernard-Tessier","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:47:12Z","timestamp":1759484832000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,12]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/jitc-2020-000713"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000713","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}